Abstract Library

#4579 Real-world effectiveness of lanreotide autogel in patients with advanced gastroenteropancreatic neuroendocrine tumours with antigen Ki-67 proliferation index above and below 10%: The KINETICS study

Introduction: The somatostatin analogue lanreotide is an established treatment option for patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) with a Ki-67 proliferation index (Ki-67)

Conference:

Presenting Author: Vandamme T

Authors: Vandamme T, Gerard L, Del Olmo-Garcia M, de Mestier L, Kiesewetter B,

Keywords: effectiveness, gastroenteropancreatic neuroendocrine tumour, GEP-NET, Ki-67 proliferation index, Ki-67, lanreotide, somatostatin analogue, somatostatin, real-world,

#4518 Efficacy and safety of cabozantinib (CABO) for advanced Grade 3 (G3) neuroendocrine tumours (NETs) after progression on prior therapy: Subgroup analysis of the phase III CABINET trial (Alliance A021602)

Introduction: Well-differentiated G3 NETs have been described as a distinct category recently, and randomised data regarding efficacy of therapy are scarce. In the phase 3 CABINET trial (NCT03375320), CABO significantly prolonged progression-free survival (PFS) compared with placebo (PB) in patients (pts) with advanced, previously treated, progressive well-differentiated extra-pancreatic NETs (epNETs) and pancreatic NETs (pNETs) of all grades (Chan et al., NEJM, 2024).

Conference:

Presenting Author: Strosberg J

Authors: Strosberg J, Zemla T, Geyer S, Pulsipher S, Behr S,

Keywords: cabozantinib, grade 3 neuroendocrine tumour, pancreatic neuroendocrine tumour, extra-pancreatic neuroendocrine tumour,

#4342 A real-world retrospective analysis to evaluate the efficacy and safety of surufatinib in the treatment of unresectable, locally advanced or metastatic neuroendocrine neoplasms in China

Introduction: The incidence of NENs is on the rise. In NECs, research on surufatinib is still scarce.

Conference:

Presenting Author:

Authors: Liu S, Zhang L, Liu B, Liu Q,

Keywords: neuroendocrine neoplasm, surufatinib, neuroendocrine carcinoma, neuroendocrine tumour, real-world study,

#4295 Are patients on somatostatin analogue therapy receiving high quality holistic cancer nursing care?

Introduction: SSA is indicated for the treatment of G1 and some G2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs) of midgut, pancreatic or unknown origin in adult patients with unresectable locally advanced or metastatic disease. As these types of cancer have much lower proliferation rates than common cancers, they are not exclusively considered cancer. It is hypothesised these patients may subsequently receive sub-standard cancer care. Furthermore, patients who are diagnosed with metastatic G3 neuroendocrine cancers will require systemic treatment with significant side effect profiles impacting negatively on quality of life.

Conference:

Presenting Author:

Authors: Wotherspoon I,

Keywords: Cancer nursing,

#4246 Prevalence of germline mutations in pancreatic neuroendocrine tumors

Introduction: Approximately 10% of pancreatic neuroendocrine tumors (PanNETs) develop due to inherited syndromes. However, generally genetic counseling and testing is not performed routinely and little accumulated on the prevalence of PanNETs associated with the presence of germline mutations.

Conference:

Presenting Author:

Authors: Salimgereeva D, Feidorov I, Konyakhina A,

Keywords: PanNET, GENOME, NGS, CHEK2, MEN1,